Long-Term Results Confirm Subcutaneous Trastuzumab ’s Efficacy in HER2+ Breast Cancer

The long-term results of the phase III HannaH trial confirmed the similarity between the subcutaneous and intravenous formulation of trastuzumab in patients with HER2+ breast cancer.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news

Related Links:

Conditions:   Receptors, Estrogen;   Genes, Erbb-2;   Breast Neoplasms Interventions:   Drug: Palbociclib (75, 100, 125 milligram [mg]);   Drug: H3B-6545 (300, 450 mg) Sponsors:   H3 Biomedicine Inc.;   Eisai Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: Available online 26 February 2020Source: Seminars in Cancer BiologyAuthor(s): Caterina Marchiò, Laura Annaratone, Ana Marques, Laura Casorzo, Enrico Berrino, Anna Sapino
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) has accepted the company's Biologics License Application (BLA) for the fixed-dose combination (FDC) of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subcutaneous (SC) injection in combination with intravenous (IV) chemotherapy,
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news
We present our OS implantation method in detail. The re-transplantation rate of TN tumors in each transplant site was significantly higher in OS when compared to SQ tumors (70.1% vs. 32.1%,p 
Source: Journal of Mammary Gland Biology and Neoplasia - Category: Cancer & Oncology Source Type: research
Oncology News Burst
Source: FDA Center for Drug Evaluation and Research - What's New - Category: Drugs & Pharmacology Authors: Source Type: news
Conditions:   Receptors, Estrogen;   Genes, Erbb-2;   Breast Neoplasms Interventions:   Drug: Palbociclib (75, 100, 125 milligram [mg]);   Drug: H3B-6545 (300, 450 mg) Sponsors:   H3 Biomedicine Inc.;   Eisai Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
The FDA approved a supplemental new drug application for neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received at least 2 prior anti-HER2-based regimens in the metastatic setting.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
AbstractThe median age for breast cancer diagnosis is 62  years, but a disproportionate number of patients are over the age of 75 years and the majority of those have hormone receptor-positive, human epidermal growth factor receptor-2 (HER2)-negative cancers. This review provides a logical algorithm to guide providers through the many complicated issue s involved in adjuvant systemic therapy decisions in older patients with hormone receptor-positive, HER2-negative breast cancer. For this subtype of breast cancer, the mainstay of treatment is surgery and adjuvant endocrine therapy with tamoxifen or an aromata...
Source: Drugs and Aging - Category: Geriatrics Source Type: research
Conclusion: Eribulin is an effective new treatment option in heavily pretreated MBC, with a manageable toxicity profile. Our results confirm that treatment with eribulin is feasible and safe in real-world patients.
Source: Indian Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
Basel, 25 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for the fixed-dose combination (FDC) of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subc utaneous (SC) injection in combination with intravenous (IV) chemotherapy, for the treatment of eligible patients with HER2-positive breast cancer. The BLA for the FDC is based on results from the phase III FeDeriCa study, which demonstrated non-inferior levels of Perjeta in the blood (phar...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | HER2 | Herceptin